Through our network of global connections, we aim to make knowledge not just available, but valuable. We want to help you acquire expertise that can be directly applied to your practice. Explore the various medical education resources below:
Optimizing care with CAR T-cell therapy now and in the future for patients with ...
Get an update on chimeric antigen receptor (CAR) T-cell therapy for B-cell malignancies, including guidance on referral and toxicity management, in these interviews with five experts.
CAR-T Meeting 2021 | CAR-T vs. BiTEs in B-cell malignancies
Marion Subklewe, MD, LMU Hospital Munich, Munich, Germany, compares CAR T-cells to bispecific T-cell engagers (BiTEs). Firstly, Prof. Subklewe highlights that there are no randomized trials in any disease comparing CAR T-cells to BiTEs.
CAR-T cell therapy in the real world (EHA25 Virtual)
Managing complex CAR-T cell treatments in the clinical practice may be challenging, however, several real-world data are currently available. Listen to Catherine Thieblemont discussing the main issues of CAR-T therapy delivery and results in the real life during the past EHA25 Virtual congress.
ASH Educational Highlights: Focus on Immunotherapy
We've selected a series of educational papers from the ASH Educational Program, covering different aspects of immunology and immunotherapy in lymphomas, leukemias and myeloma.
New module from the EHA CAR-T Program: CAR-T therapy for hematopoietic malignanc...
This new course covers indications of CAR-T therapy, from the more common ones to the newest. Landmark trials are briefly covered, but also preliminary studies in diseases such as CLL. Barriers to CAR-T and patient selection issues complete the course.
Lymphodepletion optimization for CAR T-cell therapy
At the 8th annual meeting of the Society of Hematologic Oncology (SOHO), Elizabeth Budde presented how the process of lymphodepletion can be optimized to aid persistence and efficacy of infused CAR T-cells.
2nd European CAR T Cell Meeting (Jan 30 - Feb 1, 2020) Report
Sections: (1) The clinical landscape for CAR-T, and current developments in Europe, (2) The global efforts to improve CAR T-cell therapy and (3) Regulatory considerations and directions for the European CAR-T landscape
ERIC 2020 | Developing T-cell based therapies for CLL treatment
Arnon Kater, MD, PhD, University of Amsterdam, Amsterdam, The Netherlands, discusses T-cell based therapy to treat chronic lymphocytic leukemia (CLL).
Exploring the Future of CAR T-Cell Therapy in Multiple Myeloma
C. Ola Landgren, MD, PhD, chief of Myeloma Service and hematologic oncologist at Memorial Sloan Kettering Cancer Center, discusses what is next for chimeric antigen receptor (CAR) T-cell therapy in the multiple myeloma landscape.
Cancer immunotherapy update
Because cancer treatment (surgery, radiation, and chemotherapy) frequently fails, researchers began asking why patients’ immune systems don’t respond to cancer cells like they do to bacteria and viruses.